Files and links (1)
Published, Version of Record (VoR)CC BY-NC V4.0, Open
Journal article
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry
Dermatology and therapy, v 12(1), pp 97-119
01 Jan 2022
PMID: 34822121
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Introduction Guselkumab is approved for the treatment of both moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA) in the USA. However, little is known about patients initiating guselkumab in a real-world setting. The objective of this study was to describe baseline characteristics among patients with plaque psoriasis who initiated guselkumab at or after enrollment in CorEvitas' Psoriasis Registry. Methods Adult patients who initiated guselkumab in the Psoriasis Registry between July 18, 2017 and November 6, 2018 were included. Demographics, disease characteristics, and patient-reported outcome measures (PROMs) were assessed at the time of guselkumab initiation (baseline). Patients with psoriasis were stratified according to the number of previously received biologics (0 to 4+) for comparison. A subset of patients with psoriasis and concomitant dermatologist-diagnosed PsA were stratified into biologic-naive and biologic-experienced groups. Results Among 687 patients with psoriasis who initiated guselkumab, biologic-naive patients and those with four or more prior biologics had the most severe disease and the worst PROM scores at baseline. Among 251 patients with concomitant dermatologist-diagnosed PsA, biologic-naive patients had more severe disease and worse PROM scores than biologic-experienced patients. Conclusions These findings highlight important differences in baseline characteristics according to biologic experience among patients with plaque psoriasis with or without concomitant PsA initiating guselkumab in a real-world setting.
Metrics
Details
- Title
- Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry
- Creators
- Jessica A. Walsh - University of UtahKristina Callis Duffin - Univ Utah, Salt Lake City, UT USAAbby S. Van Voorhees - Eastern Virginia Medical SchoolSoumya D. Chakravarty - Drexel UniversityTimothy Fitzgerald - Janssen Scientific Affairs LLC, Horsham, PA, 19044, USA. TFitzg11@its.jnj.com.Amanda Teeple - Janssen Scientific Affairs LLC, Horsham, PA, 19044, USA.Katelyn Rowland - Janssen Scientific Affairs LLC, Horsham, PA, 19044, USA.Jonathan Uy - Janssen Global Services, LLC Horsham PA USARobert R. McLean - CorEvitas LLC, Waltham, MA, USA.Wendi Malley - CorEvitas LLC, Waltham, MA, USA.Angel Cronin - CorEvitas LLC, Waltham, MA, USA.Joseph F. Merola - Brigham and Women's Hospital
- Publication Details
- Dermatology and therapy, v 12(1), pp 97-119
- Publisher
- Springer Nature
- Number of pages
- 23
- Grant note
- Bristol Myers Squibb; Bristol-Myers Squibb Ortho Dermatologics Novartis Chugai Eli Lilly and Company; Eli Lilly Janssen; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc AbbVie GSK; GlaxoSmithKline Pfizer Inc.; Pfizer Sun Regeneron Arena; Australian Renewable Energy Agency (ARENA) Gilead; Gilead Sciences LEO; LEO Pharma Celgene; Bristol-Myers Squibb; Celgene Corporation CorEvitas, LLC Amgen Sanofi Boehringer Ingelheim UCB; UCB Pharma SA Janssen Biotech, Inc.; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc Genentech; Roche Holding
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Rheumatology
- Web of Science ID
- WOS:000722559200001
- Scopus ID
- 2-s2.0-85119866416
- Other Identifier
- 991019167452904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Dermatology